A formal position statement from the Australian Rheumatology Association welcomes the introduction of biosimilars to the market but reiterates the need for better pharmacovigilance. The statement published yesterday urges the government to commit to an enhanced program of surveillance and pharmacovigilance for biosimilars as soon as possible. “Prescribers must also have information on what is ...
ARA position statement welcomes biosimilars but urges careful prescribing
By Tony James
25 Nov 2016